936 Results

People

  1. Tap
    Tap
  2. D'Angelo
    D'Angelo
  3. Gounder
    Gounder
  4. Chi
    Chi
  5. Dickson
    Dickson
  6. Antonescu
    Antonescu
  7. Keohan
    Keohan
  8. Singer
    Singer
  9. Kelly
    Kelly
  10. Qin
    Qin

Groups

  1. Department of Medicine (936)
  2. Sarcoma Service (936)
  3. Solid Tumor Oncology Division (936)
  4. GSK Faculty (336)
  5. Tow Center for Developmental Oncology (TCDO) (304)
  6. Hematologic Malignancies, Division of (289)
  7. Department of Pathology and Laboratory Medicine (237)
  8. Human Oncology and Pathogenesis Program (232)
  9. Surgery (199)
  10. Sarcoma Surgeons (142)
  1. "Sarcoma Service"
Formats
  1. Journal Article (444)
  2. Meeting Abstract (429)
  3. Review (26)
  4. Editorial (8)
  5. Guidelines (8)
  6. Book Section (6)
  7. Miscellaneous (6)
  8. Research Letter (6)
  9. Correspondence (2)
  10. Book Whole (1)
Groups
  1. Department of Medicine (936)
  2. Sarcoma Service (936)
  3. Solid Tumor Oncology Division (936)
  4. GSK Faculty (336)
  5. Tow Center for Developmental Oncology (TCDO) (304)
  6. Hematologic Malignancies, Division of (289)

More Groups

People
  1. William Tap (372)
  2. Sandra D'Angelo (252)
  3. Mrinal Gounder (228)
  4. Ping Chi (172)
  5. Mark Dickson (169)
  6. Cristina Antonescu (135)

More People

Years
  1. 2025 (27)
  2. 2024 (87)
  3. 2023 (79)
  4. 2022 (116)
  5. 2021 (76)
  6. 2020 (90)

More Years

Publications
  1. Journal of Clinical Oncology (272)
  2. Annals of Oncology (70)
  3. Clinical Cancer Research (60)
  4. Cancer Research (31)
  5. Journal for ImmunoTherapy of Cancer (25)
  6. Cancer (19)

More Publications

Publishers
  1. American Society of Clinical Oncology (286)
  2. American Association for Cancer Research (107)
  3. Oxford University Press (91)
  4. Elsevier Inc. (59)
  5. Nature Publishing Group (41)
  6. Springer (40)

More Publishers

Results (936)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ZENYTH-ESO Substudy 1 (GSK3901961), cohort 1: A first-in-human study to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with non-small cell lung cancer
    Meeting Abstract

    Wermke, M.; Ullrich, R.; Yachnin, J.; Mielke, S.; Patel, R.; Yushak, M. L.; Schoenfeld, A. J.; Desai, J.; Altan, M.; D'angelo, S. P.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma, myxoid/round cell liposarcoma and nonsmall cell lung cancer [Substudy 1 (GSK3901961) and Substudy 2 (GSK3845097)]
    Meeting Abstract

    Ullrich, R.; Wermke, M.; Yachnin, J.; Mielke, S.; Patel, R.; Yushak, M. L.; Schoenfeld, A. J.; Desai, J.; Altan, M.; D'Angelo, S. P.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Comparison of a STIR- and T1-weighted-based radiomics model to differentiate between plexiform neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis type 1 (NF1)
    Meeting Abstract

    Ly, I.; Liu, T.; Cai, W.; Michaels, O.; Kwon, D.; Bredella, M.; Jordan, J.; Borcherding, D.; Boswell, D.; Burgess, C.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Navtemadlin (KRT-232) in combination with avelumab for patients with anti-PD-1/L1 treatment-naïve TP53(WT) Merkel cell carcinoma (MCC)
    Meeting Abstract

    Wong, M. K.; Burgess, M.; Chandra, S.; Schadendorf, D.; Silk, A.; Olszanski, A. J.; Grob, J. J.; Jang, S.; Grewal, J. S.; Lewis, K. D.; more...
    Journal of Investigative Dermatology (2022)

    Fulltext@MSK | Save
  • ADAM Trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in Merkel cell carcinoma patients with lymph node metastases; NCT03271372
    Meeting Abstract

    Chen, W.; Bhatia, S.; Brohl, A. S.; Chandra, S.; Dakhil, S.; Fecher, L. A.; Gao, L.; Gooley, T. A.; Hanna, G. J.; Hibbert, R.; more...
    Journal of Investigative Dermatology (2022)

    Fulltext@MSK | Save
  • DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT)
    Meeting Abstract

    Kasper, B.; Ratan, R.; Alcindor, T.; Schoeffski, P.; van Der Graaf, W. T. A.; Wilky, B. A.; Riedel, R. F.; Lim, A.; Smith, L. M.; Moody, S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Initial results of phase II/III trial of AL102 for treatment of desmoid tumors (DT)
    Meeting Abstract

    Gounder, M. M.; Jones, R. L.; Chugh, R.; Agulnik, M.; Singh, A.; Van Tine, B. A.; Andelkovic, V.; Choy, E.; Lewin, J.; Ratan, R.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase II expansion
    Meeting Abstract

    Blay, J. Y.; Gelderblom, H.; Rutkowski, P.; Wagner, A.; van de Sande, M.; Gonzalez, A. F.; Stacchiotti, S.; Le Cesne, A.; Alcindor, T.; Serrano, C.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of vimseltinib in tenosynovial giant cell tumour (TGCT): Long-term phase I update
    Meeting Abstract

    Gelderblom, H.; Abdul Razak, A.; Martin-Broto, J.; Wilky, B. A.; Rutkowski, P.; Narasimhan, S.; Vallee, M.; Sharma, M.; Ruiz-Soto, R.; Sherman, M. L.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2-p53 antagonist BI 907828 in patients (pts) with solid tumours
    Meeting Abstract

    Schoeffski, P.; Yamamoto, N.; Bauer, T.; Patel, M.; Gounder, M. M.; Geng, J.; Sailer, R.; Jayadeva, G.; Lorusso, P.
    Annals of Oncology (2022)

    Fulltext@MSK | Save